5-甲基-1,3-二苯-1H-吡唑-4-羧酸 | 15409-48-0

• 物质功能分类: 有机原料 - 羧酸类化合物及衍生物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 5-甲基-1,3-二苯-1H-吡唑-4-羧酸
• 英文名称: 5-methyl-1,3-diphenyl-1H-pyrazole-4-carboxylic acid
• 英文别名: 1,3-Diphenyl-5-methyl-pyrazol-4-carbonsaeure；5-methyl-1,3-diphenylpyrazole-4-carboxylic acid
• CAS: 15409-48-0
• 化学式: C₁₇H₁₄N₂O₂
• mdl: MFCD00510082
• 分子量: 278.31
• InChiKey: FWIYNXGMTSTQBJ-UHFFFAOYSA-N

物化性质

• 熔点：
  196°C

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  21
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  55.1
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2933199090
• 储存条件：
  室温

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 5-Methyl-1,3-diphenyl-1H-pyrazole-4-carboxylic acid
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 5-Methyl-1,3-diphenyl-1H-pyrazole-4-carboxylic acid
CAS number: 15409-48-0

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels, refrigerated.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C17H14N2O2
Molecular weight: 278.3

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  5-甲基-1,3-二苯-1H-吡唑-4-羧酸 在 氯化亚砜 作用下， 反应 1.0h， 生成 1,3-diphenyl-5-methylpyrazole-4-carboxylic chloride
  参考文献：
  名称：

  Search for antialcoholic agents in the series of amides of substituted pyrazole-4-carboxylic and pyrazole-4-acetic acids

  摘要：

  DOI：

  10.1007/bf00766389
• 作为产物：
  描述：

  苯甲醛苯腙 在 sodium ethanolate 、 zinc(II) chloride 作用下， 生成 5-甲基-1,3-二苯-1H-吡唑-4-羧酸
  参考文献：
  名称：

  Minunni; Lazzarini, Atti della Accademia Nazionale dei Lincei, Classe di Scienze Fisiche, Matematiche e Naturali, Rendiconti, 1906, vol. <5> 15 I, p. 19

  摘要：

  DOI：

文献信息

• Inhibitors of P2X3
  申请人：Brotherton-Pleiss E. Christine

  公开号：US20070037974A1

  公开（公告）日：2007-02-15

  Compounds of formula 1 are modulators of P2X3 useful for the treatment of pain and genito-urinary, gastrointestinal, and respiratory disorders: wherein R 1 is —C(═S)CH 3 , pyridyl, pyrimidinyl, pyrazinyl, thiazolyl, furyl, furylcarbonyl, acetyl, or carbamoyl; R 2a and R 2b are independently H, methyl, or ethyl; R 3 is H or methyl; Y is a bond, —(CR 4 R 5 ) n — or —CR 4 ═CR 5 —; wherein R 4 and R 5 are each independently H or methyl and n is 1 or 2; X is N or CH; A is phenyl, 5-membered heterocyclyl, or 6-membered heterocyclyl; R 6 , R 7 and R 8 are each independently H, halo, lower alkyl, cycloalkyl, alkylthio, alkylthio-lower alkyl, alkylsulfonyl-lower alkyl, di(lower alkyl)amino-lower alkyl, morpholinyl-lower alkyl, 4-methyl-piperazinyl-methyl, trifluoromethyl, pyridyl, tetrazolyl, thiophenyl, phenyl, biphenyl, or benzyl (where thiophenyl, phenyl and benzyl are substituted with 0-3 lower alkyl, halo, sulfonamido, trifluoromethyl, lower alkoxy or lower alkylthio) or R 6 and R 7 together form a 5-membered or 6-membered carbocyclic or heterocyclic ring substituted with 0-3 substituents selected from the group consisting of lower alkyl, lower alkoxy, oxo, halo, thiophenyl-lower alkyl, phenyl, benzyl (where phenyl and benzyl are substituted with 0-3 lower alkyl, halo, sulfonamido, trifluoro-methyl, lower alkoxy, lower alkylthio, amino-lower alkyl, lower alkylamino-lower alkyl, or di(lower alkyl)amino-lower alkyl); and pharmaceutically acceptable salts thereof; wherein when R 1 is pyrimidin-2-yl, X is N, Y is a bond and A is oxazol-5-yl the carbon atom at position 4 in said oxazol-5-yl is not substituted by propyl when the carbon atom at position 2 in said oxazol-5-yl is substituted by substituted phenyl and the carbon atom at position 4 in said oxazol-5-yl is not substituted by phenyl when the carbon atom at position 2 is substituted by unsubstituted or substituted phenyl.

  式1的化合物是P2X3的调节剂，用于治疗疼痛和泌尿生殖、胃肠和呼吸系统疾病： 其中 R 1 为—C(═S)CH 3 ，吡啶基，嘧啶基，吡嗪基，噻唑基，呋喃基，呋喃甲酰基，乙酰基或氨基甲酰基；R 2a 和R 2b 独立地为H，甲基或乙基；R 3 为H或甲基；Y为键，—(CR 4 R 5 ) n —或—CR 4 ═CR 5 —；其中R 4 和R 5 各自独立地为H或甲基，n为1或2；X为N或CH；A为苯基，5-成员杂环基或6-成员杂环基；R 6 ，R 7 和R 8 各自独立地为H，卤素，低碳基，环烷基，烷基硫醚，烷基硫醚-低碳基，烷基磺酰基-低碳基，二(低碳基)氨基-低碳基，吗啉基-低碳基，4-甲基哌嗪基-甲基，三氟甲基，吡啶基，四唑基，噻吩基，苯基，联苯基或苄基（其中噻吩基，苯基和苄基被0-3个低碳基，卤素，磺酰胺基，三氟甲基，低烷氧基或低烷硫基取代）或R 6 和R 7 一起形成一个被0-3个取自由低碳基，低烷氧基，氧代基，卤素，噻吩基-低碳基，苯基，苄基（其中苯基和苄基被0-3个低碳基，卤素，磺酰胺基，三氟甲基，低烷氧基，低烷硫基，氨基-低碳基，烷基氨基-低碳基或二(低碳基)氨基-低碳基取代）的5-成员或6-成员碳环或杂环取代环；及其药学上可接受的盐；其中当R 1 为嘧啶-2-基时，X为N，Y为键，A为噁唑-5-基时，所述噁唑-5-基中位置4的碳原子在所述噁唑-5-基中位置2的碳原子被取代的苯基取代时不被丙基取代，且所述噁唑-5-基中位置4的碳原子在位置2被取代的苯基取代时不被苯基取代。
• The first chemoselective tandem acylation of the Blaise reaction intermediate: a novel method for the synthesis of α-acyl-β-enamino esters, key intermediate for pyrazoles
  作者：Yu Sung Chun、Ki Kon Lee、Young Ok Ko、Hyunik Shin、Sang-gi Lee

  DOI：10.1039/b813369g

  日期：——

  The Blaise reaction intermediate, a zinc bromide complex of β-enamino ester, could be activated in situ by addition of a stoichiometric or catalytic amount of n-BuLi to allow chemoselective tandem C2-acylation providing α-acyl-β-enamino esters, which are valuable intermediates for the syntheses of tri- and tetrasubstituted pyrazoles.

  布雷兹反应中间体是一种β-氨基酯的溴化锌复合物，可以通过添加计量或催化量的正丁基锂(n-BuLi)在原位激活，从而实现化学选择性的串联C2-酰基化，生成α-酰基-β-氨基酯，这些是合成三取代和四取代吡唑的重要中间体。
• PYRAZOLE SYNTHESIS BY COUPLING OF CARBOXYLIC ACID DERIVATIVES AND ENAMINES
  申请人：Neumann Julia

  公开号：US20130012715A1

  公开（公告）日：2013-01-10

  The invention describes a novel process for synthesizing pyrazoles by means of oxidative conversion of enamines with suitable N-containing carboxylic acid derivatives.

  这项发明描述了一种通过氧化转化烯胺和适当的含氮羧酸衍生物合成吡唑的新方法。
• Novel pyrazole integrated 1,3,4-oxadiazoles: Synthesis, characterization and antimicrobial evaluation
  作者：Srikantamurthy Ningaiah、Umesha K. Bhadraiah、Shridevi D. Doddaramappa、Shubakara Keshavamurthy、Chethan Javarasetty

  DOI：10.1016/j.bmcl.2013.11.029

  日期：2014.1

  A novel series of 2-(5-methyl-1,3-diphenyl-1H-pyrazol-4-yl)-5-phenyl-1,3,4-oxadiazoles 7(a–m) were synthesized either by cyclization of N′-benzoyl-5-methyl-1,3-diphenyl-1H-pyrazole-4-carbohydrazide 4a using POCl3 at 120 °C or by oxidative cyclization of hydrazones derived from various arylaldehyde and (E)-N′-benzylidene-5-methyl-1,3-diphenyl-1H-pyrazole-4-carbohydrazide 5(a–d) using chloramine-T as

  通过环戊基环化反应合成了一系列新的2-（5-甲基-1,3-二苯基-1 H-吡唑-4-基）-5-苯基-1,3,4-恶二唑7（a - m）。使用POCl 3在120°C或通过氧化环化衍生自各种芳醛和（E）-N'-苄叉的ne的N'-苯甲酰基-5-甲基-1,3-二苯基-1 H-吡唑-4-碳酰肼4a -5-甲基-1,3-二苯基-1 H-吡唑-4-碳酰肼5（a – d）使用氯胺-T作为氧化剂。新合成的化合物通过分析和光谱（IR，1 H NMR，13 C NMR和LC-MS）方法进行表征。评价合成的化合物的抗微生物活性并将其与标准药物进行比较。这些化合物显示出对弱抗菌活性的作用。在合成的化合物中，化合物7m成为一种有效的抗菌剂，而化合物7d，7f，7i和7l则显示出良好至中等的活性。化合物对细菌的最低抑菌浓度为20–50μgmL -1，而对细菌的最低抑菌浓度为25–55μgmL -1对抗真菌。标题化合物代表一类新型的有效抗菌剂。
• Tertiary Carbinamines Having Substituted Heterocycles Which Are Active As Beta-Secretase Inhibitors For The Treatment Of Alzheimer's Disease
  申请人：McGaughey Georgia B.

  公开号：US20080139538A1

  公开（公告）日：2008-06-12

  The present invention is directed to tertiary carbinamine compounds having substituted heterocycles, which are inhibitors of the beta-secretase enzyme, and are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases in which the beta-secretase enzyme is involved.

  本发明涉及具有取代杂环的三级碳胺化合物，它们是β-分泌酶酶的抑制剂，并且在治疗β-分泌酶酶参与的疾病，如阿尔茨海默病方面有用。本发明还涉及包括这些化合物的制药组合物以及在治疗β-分泌酶酶参与的疾病方面使用这些化合物和组合物。